Pancreatic Cancer Research

ResearcherStanford MedicineActive in the last 2 years

George A. Poultsides

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7584-0405; OpenAlex author ID A5052324083, A5065551581; NIH RePORTER profile ID 12594328. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 0, last author 7)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
86
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 3 papers, 1 trial · 2017: 1 paper · 2018: 5 papers, 1 trial · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 24

  1. NFAT mediates pro-tumorigenic inflammation in cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116849↗
  2. Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Last author DOI 10.1097/sla.0000000000006609↗
  3. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  4. Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.116347↗
  5. Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness. Co-author DOI 10.1016/j.gastha.2024.04.005↗
  6. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  7. Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. Co-author DOI 10.1245/s10434-023-13120-3↗
  8. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  9. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalatio… Last author DOI 10.1016/s2468-1253(20)30088-1↗
  10. Pancreatic Cancer Prognostication: From Trousseau to Thrombelastography. Co-author DOI 10.1097/sla.0000000000004139↗
  11. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. Last author DOI 10.1016/j.hpb.2018.11.008↗
  12. Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Co-author DOI 10.1097/mpa.0000000000001314↗
  13. Management of Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2017.12.287↗
  14. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Co-author DOI 10.1097/coc.0000000000000263↗
  15. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Co-author DOI 10.1245/s10434-018-6453-2↗
  16. ASO Author Reflections: Fluorescent-Guided Surgery to Augment Pancreatic Cancer Surgery. Last author DOI 10.1245/s10434-018-6904-9↗
  17. Correction to: ASO Author Reflections: Fluorescent-Guided Surgery to Augment Pancreatic Cancer Surgery. Last author DOI 10.1245/s10434-018-7065-6↗
  18. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Rando… Last author DOI 10.1245/s10434-017-5826-2↗
  19. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000470↗
  20. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Co-author DOI 10.1152/ajpgi.00035.2016↗
  21. Pancreatic Cancer Surgical Resection Margins: Molecular Assessment by Mass Spectrometry Imaging. Last author DOI 10.1371/journal.pmed.1002108↗
  22. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Co-author DOI 10.1016/j.ijrobp.2014.06.066↗
  23. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2011.09.035↗
  24. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. Co-author DOI 10.1111/j.1477-2574.2012.00496.x↗

Trials 2

  1. Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery Principal investigator NCT03384238↗
  2. Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery Principal investigator NCT02736578↗

Grants 1

  1. Highly Sensitive Detection of Occult Pancreatic Cancer Using Intraoperative Molecular Imaging R01CA273035↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brendan Christopher Visser · 10 shared papers, 2012–2026 · strength 1.14
  2. George Albert Fisher · 10 shared papers, 2012–2026 · strength 1.02
  3. Daniel Tandel Chang · 10 shared papers, 2012–2026 · strength 1.01
  4. Jeffrey Allen Norton · 8 shared papers, 2012–2026 · strength 0.85
  5. Daniel Delitto · 3 shared papers, 2025–2026 · strength 0.63
  6. Erqi Liu Pollom · 5 shared papers, 2014–2026 · strength 0.62
  7. Albert C. Koong · 7 shared papers, 2012–2023 · strength 0.55
  8. Eben Lloyd Rosenthal · 5 shared papers, 2018–2020 · strength 0.48
  9. Byrne Lee · 2 shared papers, 2025–2026 · strength 0.42
  10. Amanda Kirane · 2 shared papers, 2025–2026 · strength 0.42
  11. Maria Moozhiyil Korah · 2 shared papers, 2025–2026 · strength 0.39
  12. James Paul Agolia · 2 shared papers, 2025–2026 · strength 0.39
  13. Deshka S. Foster · 2 shared papers, 2025–2026 · strength 0.39
  14. Jason L. Guo · 2 shared papers, 2025–2026 · strength 0.39
  15. Michael Thornton Longaker · 2 shared papers, 2025–2026 · strength 0.39
  16. Chuner Guo · 2 shared papers, 2025–2026 · strength 0.39
  17. Willemieke S. F. J. Tummers · 4 shared papers, 2018–2019 · strength 0.38
  18. Alexander L. Vahrmeijer · 4 shared papers, 2018–2019 · strength 0.38
  19. Diego A.S. Toesca · 3 shared papers, 2018–2023 · strength 0.34
  20. R. Brooke Jeffrey · 2 shared papers, 2019–2023 · strength 0.25
  21. Timothy R. Donahue · 2 shared papers, 2016–2026 · strength 0.24
  22. M. Usman Ahmad · 1 shared paper, 2026 · strength 0.24
  23. Gregory M. Heestand · 1 shared paper, 2026 · strength 0.24
  24. Christina Vorvis · 2 shared papers, 2016–2024 · strength 0.23
  25. Maria Hatziapostolou · 2 shared papers, 2016–2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.